11-Ketotestosterone and 11-ketodihydrotestosterone in castration resistant prostate cancer: Potent androgens which can no longer be ignored

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Pretorius, Elzette ^a   Africander, Donita J ^a   Vlok, Maré ^a   Perkins, Meghan S ^a   Quanson, Jonathan ^a   Storbeck, Karl Heinz ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

11 KETODIHYDROTESTOSTERONE; 11 OXOTESTOSTERONE; ANDROGEN; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANDROSTANOLONE; GLUCURONOSYLTRANSFERASE; MESSENGER RNA; TESTOSTERONE; UNCLASSIFIED DRUG; 11-KETODIHYDROTESTOSTERONE; 11-KETOTESTOSTERONE; PROTEIN BINDING;

ANDROGEN METABOLISM; ANDROGEN SYNTHESIS; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; FKBP5 GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; KLK3 GENE; LNCAP CELL LINE; MALE; METABOLIC RATE; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEOMICS; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; TMPRSS2 GENE; VCAP CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; DNA RESPONSIVE ELEMENT; METABOLISM; TUMOR CELL LINE;

ANDROGENS; ANIMALS; BIOSYNTHETIC PATHWAYS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN BINDING; RECEPTORS, ANDROGEN; RESPONSE ELEMENTS; TESTOSTERONE;

EID: 84979530001     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0159867     Document Type: Article

References (54)

1. Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: Geographical distribution and secular trends. Mol Nutr Food Res. 2009; 53(2):171-84. doi: 10.1002/mnfr.200700511 PMID: 19101947
2. Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, et al. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008; 112(6):1247-53. doi: 10.1002/cncr.23304 PMID: 18293426
3. Zlotta A, Debruyne FMJ. Expert opinion on optimal testosterone control in prostate cancer. Eur Urol Suppl. 2005; 4(8):37-41.
4. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol. 2004; 164(1):217-27. PMID: 14695335
5. Yuan X, Balk SP. Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol Semin Orig Investig. Elsevier Inc.; 2009; 27(1):36-41.
6. Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab. Elsevier Ltd; 2010; 21(5):315-24.
7. Cabot RC, Harris NL, Rosenberg ES, Shepard J-AO, Cort AM, Ebeling SH, et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med. 2012; 367(13):1187-97. PMID: 22894553
8. Attard G, Reid AHM, A'Hern R, Parker C, Oommen NB, Folkerd E, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009; 27(23):3742-8. doi: 10.1200/JCO.2008.20.0642 PMID: 19470933
9. De Bono J, Logothetis C, Molina A, Fizazi K, North S, Chu L, et al. Arbiraterone and Increased Survival in Metastatic Prostate Cancer. N Engl J Med. 2011; 364(21):1995-2005. doi: 10.1056/NEJMoa1014618 PMID: 21612468
10. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012; 13(10):983-92. doi: 10.1016/S1470-2045(12)70379-0 PMID: 22995653
11. Luu-The V, Bélanger A, Labrie F. Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab. 2008; 22(2):207-21. doi: 10.1016/j.beem.2008.01.008 PMID: 18471780
12. Chang K-H, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2011; 108(33):13728-33. doi: 10.1073/pnas.1107898108 PMID: 21795608
13. Sharifi N. The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer. J Investig Med. 2012; 60(2):504-7. doi: 10.231/JIM.0b013e31823874a4 PMID: 22064602
14. Sharifi N, Auchus RJ. Steroid biosynthesis and prostate cancer. Steroids. Elsevier Inc.; 2012; 77 (7):719-26.
15. Sharifi N, Auchus RJ. Androstenedione Is the Preferred Androgen Source in Hormone Refractory Prostate Cancer - Letter. Clin Cancer Res. 2014; 20(18):4971-4971. doi: 10.1158/1078-0432.CCR-14-1123 PMID: 25225065
16. Bloem L, Storbeck K-H, Schloms L, Swart A. 11β-Hydroxyandrostenedione Returns to the Steroid Arena: Biosynthesis, Metabolism and Function. Molecules. 2013; 18(11):13228-44. doi: 10.3390/molecules181113228 PMID: 24165582
17. Rege J, Nakamura Y, Satoh F, Morimoto R, Kennedy MR, Layman LC, et al. Liquid Chromatography - Tandem Mass Spectrometry Analysis of Human Adrenal Vein 19-Carbon Steroids Before and After ACTH Stimulation. J Clin Endocrinol Metab. 2013; 98(3):1182-8. doi: 10.1210/jc.2012-2912 PMID: 23386646
18. Swart AC, Storbeck K-H. 11β-hydroxyandrostenedione: Downstream metabolism by 11βHSD, 17βHSD and SRD5A produces novel substrates in familiar pathways. Mol Cell Endocrinol. 2015; 408:114-23. doi: 10.1016/j.mce.2014.12.009 PMID: 25542845
19. Schloms L, Storbeck K-H, Swart P, Gelderblom WCA, Swart AC. The influence of Aspalathus linearis (Rooibos) and dihydrochalcones on adrenal steroidogenesis: Quantification of steroid intermediates and end products in H295R cells. J Steroid Biochem Mol Biol. Elsevier Ltd; 2012; 128(3-5):128-38.
20. Swart AC, Schloms L, Storbeck K-H, Bloem LM, Toit T Du, Quanson JL, et al. 11β-Hydroxyandrostenedione, the product of androstenedione metabolism in the adrenal, is metabolized in LNCaP cells by 5α-reductase yielding 11β-hydroxy-5α-androstanedione. J Steroid Biochem Mol Biol. Elsevier Ltd; 2013; 138:132-42.
21. Storbeck K-H, Bloem LM, Africander D, Schloms L, Swart P, Swart AC. 11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 Steroids with androgenic activity: A putative role in castration resistant prostate cancer? Mol Cell Endocrinol. Elsevier BV; 2013 Sep; 377(1-2):135-46.
22. Schauwaers K, De Gendt K, Saunders PTK, Atanassova N, Haelens A, Callewaert L, et al. Loss of androgen receptor binding to selective androgen response elements causes a reproductive phenotype in a knockin mouse model. Proc Natl Acad Sci U S A. 2007; 104(12):4961-6. PMID: 17360365
23. Brinkmann AO, Faber PW, van Rooij HC, Kuiper GG, Ris C, Klaassen P, et al. The human androgen receptor: domain structure, genomic organization and regulation of expression. J Steroid Biochem. 1989; 34(1-6):307-10. PMID: 2626022
24. Africander DJ, Storbeck K-H, Hapgood JP. A comparative study of the androgenic properties of progesterone and the progestins, medroxyprogesterone acetate (MPA) and norethisterone acetate (NET-A). J Steroid Biochem Mol Biol. Elsevier Ltd; 2014; 143:404-15.
25. Swillens S. Interpretation of binding curves obtained with high receptor concentrations: practical aid for computer analysis. Mol Pharmacol. 1995; 47(6):1197-203. PMID: 7603460
26. Africander D, Louw R, Verhoog N, Noeth D, Hapgood JP. Differential regulation of endogenous proinflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract. Contraception. Elsevier Inc.; 2011; 84(4):423-35.
27. Bohrer LR, Chen S, Hallstrom TC, Huang H. Androgens Suppress EZH2 Expression Via Retinoblastoma (RB) and p130-Dependent Pathways: A Potential Mechanism of Androgen-Refractory Progression of Prostate Cancer. Endocrinology. 2010; 151(11):5136-45. doi: 10.1210/en.2010-0436 PMID: 20881251
28. Kumagai J, Hofland J, Erkens-Schulze S, Dits NFJ, Steenbergen J, Jenster G, et al. Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis. Prostate. 2013; 73(15):1636-50. doi: 10.1002/pros.22655 PMID: 23996639
29. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics. 2012; 13(1):134.
30. Borra RC, Lotufo MA, Gagioti SM, Barros FDM, Andrade PM. A simple method to measure cell viability in proliferation and cytotoxicity assays. Braz Oral Res. 2009; 23(3):255-62. PMID: 19893959
31. Perrot S. Resazurin Metabolism Assay Is a New Sensitive Alternative Test in Isolated Pig Cornea. Toxicol Sci. 2003; 72(1):122-9. PMID: 12604841
32. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, et al. A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 1990; 173(2):534-40. PMID: 2260966
33. Li Z, Bishop AC, Alyamani M, Garcia J a., Dreicer R, Bunch D, et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature. 2015; 523(7560):347-51. doi: 10.1038/nature14406 PMID: 26030522
34. Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel E a., et al. Intratumoral De Novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011; 71(20):6503-13. doi: 10.1158/0008-5472.CAN-11-0532 PMID: 21868758
35. Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, Lin DL PK. VCaP, a cell-based model system of human prostate cancer. In Vivo (Brooklyn). 2001; 15(2):163-8.
36. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, et al. LNCaP Model of Human Prostatic Carcinoma LNCaP Model of Human Prostatic Carcinoma1. Cancer Res. 1983; 43:1809-18. PMID: 6831420
37. Launoit De Y, Veilleux R, Dufour M, Simard J, Labrie F. Characteristics of the Biphasic Action of Androgens and of the Potent Anti- proliferative Effects of the New Pure Antiestrogen EM-139 on Cell Cycle Kinetic Parameters in LNCaP Human Prostatic Cancer Cells1. Cancer Res. 1991; 51:5165-70. PMID: 1913642
38. Shao C, Wang Y, Yue H-H, Zhang Y-T, Shi C-H, Liu F an, et al. Biphasic Effect of Androgens on Prostate Cancer Cells and Its Correlation With Androgen Receptor Coactivator. J Androl. 2007; 28(6):804-12. PMID: 17581945
39. Bélanger A, Pelletier G, Labrie F, Barbier O, Chouinard S. Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endocrinol Metab. 2003; 14(10):473-9. PMID: 14643063
40. Williamson SC, Mitter R, Hepburn a C, Wilson L, Mantilla a, Leung HY, et al. Characterisations of human prostate stem cells reveal deficiency in class I UGT enzymes as a novel mechanism for castration-resistant prostate cancer. Br J Cancer. Nature Publishing Group; 2013; 109(4):950-6.
41. Wijayakumara DD, Hu DG, Meech R, McKinnon R a., Mackenzie PI. Regulation of Human UGT2B15 and UGT2B17 by miR-376c in Prostate Cancer Cell Lines. J Pharmacol Exp Ther. 2015; 354(3):417-25. doi: 10.1124/jpet.115.226118 PMID: 26163549
42. Attard G, Cooper CS, de Bono JS. Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break? Cancer Cell. Elsevier Inc.; 2009; 16(6):458-62.
43. Chang K-H, Ercole CE, Sharifi N. Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences. Br J Cancer. Nature Publishing Group; 2014; 111(7):1249-54.
44. Yazawa T, Uesaka M, Inaoka Y, Mizutani T, Sekiguchi T, Kajitani T, et al. Cyp11b1 Is Induced in the Murine Gonad by Luteinizing Hormone/Human Chorionic Gonadotropin and Involved in the Production of 11-Ketotestosterone, a Major Fish Androgen: Conservation and Evolution of the Androgen Metabolic Pathway. Endocrinology. 2008; 149(4):1786-92. PMID: 18162527
45. Bao B-Y, Chuang B-F, Wang Q, Sartor O, Balk SP, Brown M, et al. Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes. Prostate. 2008; 68(8):839-48. doi: 10.1002/pros.20749 PMID: 18302198
46. Saramäki OR, Harjula AE, Martikainen PM, Lvessella R, Tammela TLJ, Visakorpi T. TMPRSS2.ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res. 2008; 14 (11):3395-400. doi: 10.1158/1078-0432.CCR-07-2051 PMID: 18519769
47. Turcu AF, Nanba AT, Chomic R, Upadhyay SK, Giordano TJ, Shields JJ, et al. Adrenal-derived 11-Oxygenated 19-Carbon Steroids are the Dominant Androgens in Classic 21- Hydroxylase Deficiency. Eur Soc Endocrinol. 2016; 174:601-609.
48. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29(9):2002-7.
49. Willems E, Leyns L, Vandesompele J. Standardization of real-time PCR gene expression data from independent biological replicates. 2008; 379:127-9.
50. Jiang M, Ma Y, Chen C, Fu X, Yang S, Li X, et al. Androgen-responsive gene database: integrated knowledge on androgen-responsive genes. Mol Endocrinol. 2009; 23(11):1927-33. doi: 10.1210/me.2009-0103 PMID: 19762544
51. Vellaichamy A, Sreekumar A, Strahler JR, Rajendiran TM, Yu J, Varambally S, et al. Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases. PLoS One. 2009; 4(9):e7075. doi: 10.1371/journal.pone.0007075 PMID: 19763266
52. Lin H, Lu JP, Laflamme P, Qiao S, Shayegan B, Bryskin I, Monardo L, Wilson BC, Singh G PJ. Interrelated in vitro effects of androgens, fatty acids and oxidative stress in prostate cancer: a mechanistic model supporting prevention strategies. Int J Oncol. 2010; 37(4):761-6. PMID: 20811696
53. Marques RB, Dits NF, Erkens-Schulze S, van Ijcken WFJ, van Weerden WM, Jenster G. Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines. PLoS One. 2011; 6(8):e23144. doi: 10.1371/journal.pone.0023144 PMID: 21829708
54. Rowland JG, Robson JL, Simon WJ, Leung HY, Slabas AR. Evaluation of an in vitro model of androgen ablation and identification of the androgen responsive proteome in LNCaP cells. Proteomics. 2007; 7 (1):47-63. PMID: 17152098